RYAN SPERL: Open Payments
NPI 1912410408 · ODESSA, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,228 in 116 payments from 45 companies in 2025. Trend: 2023 $3,900 · 2024 $3,211 · 2025 $4,228
Food & beverage: $4,228
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 12 | $448 |
| AstraZeneca Pharmaceuticals LP | 9 | $371 |
| Janssen Scientific Affairs, LLC | 2 | $201 |
| Stemline Therapeutics Inc. | 4 | $178 |
| Incyte Corporation | 4 | $177 |
| GlaxoSmithKline, LLC. | 5 | $169 |
| Genmab U.S., Inc. | 3 | $159 |
| SERVIER PHARMACEUTICALS LLC | 2 | $159 |
| Pharmacosmos Therapeutics Inc. | 5 | $159 |
| Exelixis Inc. | 3 | $145 |
Products named: RYBREVANT, DARZALEX, Orserdu, MONOFERRIC, MONJUVI, JEMPERLI, CABOMETYX, OPDIVO.
Industry payments across TX — which companies pay providers there.
